Psoriasis vulgaris in patients with a recent history of neoplasia: safety of interleukin-23 inhibitors. A multicentre retrospective study
Year: 2025
Type: article
Study design: Observational Study
Abstract: BACKGROUND: The management of psoriasis in patients with a history of cancer remains debated, especially for the limited literature available. Given the lack of large, well-designed studies focused on this patient group, real-world clinical experiences and expert insights serve as crucial resources for guiding informed treatment decisions. This issue particularly regards the newest anti-interleukin (IL) drugs available, such as those targeting IL-23. OBJECTIVES: To analyse a real-world population of patients with psoriasis undergoing biologic treatment with anti-IL-23 drugs who also have a concurrent cancer diagnosis. METHODS: A retrospective, observational, multicentre study was conducted, enrolling adult patients with moderate-to-severe plaque psoriasis and a personal history of malignancy. The patients were undergoing any anti-IL-23 treatment approved for psoriasis (guselkumab, risankizumab or tildrakizumab). RESULTS: In total, 198 patients were enrolled. Among these, 67 (33.8%) had a history of malignancy within the past 5 years, whereas 131 (66.2%) had been diagnosed with cancer prior to that time. During the period of the study, six patients (3.0%) experienced progression or recurrence of their existing neoplasia. Moreover, six (3.0%) were diagnosed with a new neoplasia during the study period, discontinuing biologic treatment in only two cases. A subanalysis investigating the relationship between comorbidities and the incidence of neoplastic progression or recurrence during therapy, as well as the development of a new neoplasia, did not show any statistically significant associations. Similarly, significant associations between previous treatments and increased risk of cancer recurrence, progression or development were not found. CONCLUSIONS: Our real-life experience is the largest study investigating the use of anti-IL-23 agents and the risk of cancer recurrence, progression and development in patients with a history of cancer. This study confirms their safety also in this cohort of patients.
DOI: 10.1093/ced/llaf184
Authors: Francesca Satolli, Silvia Gerosa, Martina Burlando, Emanuele Claudio Cozzani, Claudia Lasagni, Marco Manfredini, Alessandra Narcisi, Angelo Valerio Marzano, Carlo Giovanni Carrera, Matteo Megna, Annalisa Cagni, Maria Esposito, Maria Concetta Fargnoli, Vito Di Lernia, Francesca Peccerillo, Marco Romanelli, Emanuele Trovato, Paolo Amerio, Andrea Carugno, Giovanna Brunasso, Giulia Rech, Riccardo Balestri, Luca Mastorino, Pietro Quaglino, Marco Brusasco, Claudio Feliciani
Institutions: University of Parma, University of Siena, Ospedale Santa Maria alle Scotte, University of Modena and Reggio Emilia, Humanitas University, IRCCS Humanitas Research Hospital, University of Milan, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Federico II University Hospital, University of Naples Federico II, Istituti di Ricovero e Cura a Carattere Scientifico, University of L'Aquila, Santa Maria Nuova Hospital, University of Chieti-Pescara, University of Insubria, Ospedale Villa Scassi, University of Turin, Azienda Socio Sanitaria Territoriale Santi Paolo e Carlo
Language: English
Subfield: Immunology
Field: Immunology and Microbiology
Domain: Life Sciences
Open Access status: hybrid
Estimated APC paid: $3,354
OpenAlex ID: W4411329286